CDKN2A and neoplasm: To evaluating the roles of CI and CII in tumor proliferation and the anti-tumor immune response, the research team generated CI (sgNdufa1) or CII (sgSdha or sgSdhc) deficient YUMM1.7 (BrafV600E/Pten−/−/Cdkn2a−/−) through targeted genetic engineering.